Teva Pharmaceutical Industries Ltd. $TEVA Shares Acquired by Sowell Financial Services LLC

Sowell Financial Services LLC raised its holdings in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 107.6% in the 4th quarter, HoldingsChannel reports. The fund owned 93,330 shares of the company’s stock after buying an additional 48,366 shares during the quarter. Sowell Financial Services LLC’s holdings in Teva Pharmaceutical Industries were worth $2,913,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Signaturefd LLC boosted its position in shares of Teva Pharmaceutical Industries by 10.7% during the 4th quarter. Signaturefd LLC now owns 12,746 shares of the company’s stock worth $398,000 after acquiring an additional 1,233 shares in the last quarter. Analyst IMS Investment Management Services Ltd. acquired a new position in shares of Teva Pharmaceutical Industries during the 4th quarter worth about $66,050,000. Frank Rimerman Advisors LLC acquired a new position in shares of Teva Pharmaceutical Industries during the 4th quarter worth about $272,000. Burns Matteson Capital Management LLC acquired a new position in shares of Teva Pharmaceutical Industries during the 4th quarter worth about $277,000. Finally, Hennion & Walsh Asset Management Inc. boosted its position in shares of Teva Pharmaceutical Industries by 7.2% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 341,985 shares of the company’s stock worth $10,673,000 after acquiring an additional 22,962 shares in the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on TEVA shares. Piper Sandler reaffirmed an “overweight” rating and set a $41.00 price objective (up from $40.00) on shares of Teva Pharmaceutical Industries in a research report on Wednesday, March 4th. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 31st. Jefferies Financial Group lifted their price target on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. Truist Financial upped their price objective on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. Finally, Scotiabank upped their price objective on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a research note on Thursday, January 29th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Teva Pharmaceutical Industries currently has a consensus rating of “Moderate Buy” and an average target price of $37.67.

Insider Buying and Selling

In other news, EVP Eliyahu Sharon Kalif sold 345,810 shares of the company’s stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $33.64, for a total value of $11,633,048.40. Following the completion of the sale, the executive vice president directly owned 57,478 shares of the company’s stock, valued at approximately $1,933,559.92. This represents a 85.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Placid Jover sold 14,150 shares of the stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $31.67, for a total transaction of $448,130.50. Following the sale, the insider owned 6,774 shares of the company’s stock, valued at $214,532.58. This trade represents a 67.63% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 920,901 shares of company stock valued at $30,056,789 in the last quarter. Corporate insiders own 0.49% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE TEVA opened at $29.75 on Tuesday. The company has a current ratio of 1.04, a quick ratio of 0.80 and a debt-to-equity ratio of 1.89. Teva Pharmaceutical Industries Ltd. has a twelve month low of $12.47 and a twelve month high of $37.35. The stock has a 50 day moving average of $32.10 and a two-hundred day moving average of $27.93. The stock has a market cap of $34.21 billion, a P/E ratio of 24.79, a P/E/G ratio of 10.13 and a beta of 0.76.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.31. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The company had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.36 billion. During the same quarter in the previous year, the business earned $0.71 earnings per share. The firm’s revenue for the quarter was up 11.4% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.